Alhazzaa Mohammed A, Mujtaba Ahmed, Aljohani Mohammed A, Alqarni Fatimah, Alsharif Roaa
Neurology, King Fahad Medical City, Riyadh, SAU.
Neurology, King Fahad Hospital, Madinah, SAU.
Cureus. 2020 Jul 27;12(7):e9415. doi: 10.7759/cureus.9415.
Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke of uncertain cause. Our study aimed to provide insight into whether testing for Fabry disease is justifiable in cryptogenic stroke patients who have no other features of the disease. Method This was a prospective study conducted at a single stroke center. We included young patients between the ages of 18 and 55 years who had confirmed and unexplained ischemic or hemorrhagic insults. Alpha-galactosidase enzyme testing was conducted in all suspected cases. Further genetic testing was performed in patients with abnormal enzyme results. Result A total of 51 patients met the inclusion criteria. The mean age was 42 years. All the included patients completed a workup of ischemia or hemorrhage. All cases had no clear etiology of their vascular events. All included patients lacked classic systemic manifestations of Fabry disease. We identified one case of borderline low α-galactosidase A (GLA) enzyme level. However, GLA genetic testing did not reveal any Fabry disease-related mutation. The study did not identify any subject with confirmed Fabry disease. Conclusion In this single-center study, we found that Fabry disease had a low prevalence among Saudi cryptogenic stroke patients who lack other systemic manifestations. Hence, Fabry testing is not generally considered in routine workup related to cryptogenic stroke.
引言
法布里病是一种代谢性贮积病,可导致包括大脑在内的多个器官出现功能紊乱。沙特中风人群中该病的患病率数据匮乏。因此,在调查病因不明的中风时,通常不会定期进行相关检测。我们的研究旨在深入了解,对于无其他该病特征的隐源性中风患者,检测法布里病是否合理。
方法
这是一项在单一中风中心进行的前瞻性研究。我们纳入了年龄在18至55岁之间、确诊且病因不明的缺血性或出血性中风患者。对所有疑似病例进行了α-半乳糖苷酶检测。酶检测结果异常的患者进一步进行了基因检测。
结果
共有51名患者符合纳入标准。平均年龄为42岁。所有纳入患者均完成了缺血或出血的检查。所有病例的血管事件均无明确病因。所有纳入患者均无典型的法布里病全身表现。我们发现1例α-半乳糖苷酶A(GLA)酶水平临界偏低的病例。然而,GLA基因检测未发现任何与法布里病相关的突变。该研究未发现任何确诊为法布里病的患者。
结论
在这项单中心研究中,我们发现法布里病在缺乏其他全身表现的沙特隐源性中风患者中的患病率较低。因此,在与隐源性中风相关 的常规检查中,一般不考虑进行法布里病检测。